Fibrinogen-tau Aggregates Exacerbate Tau Pathology and Memory Deficits in Alzheimer's Disease Model Mice

被引:0
|
作者
Wen, Tingting [1 ]
Meng, Lanxia [1 ]
Liu, Han [1 ]
Zhang, Qian [1 ]
Dai, Lijun [1 ]
Huang, Liqin [1 ]
Dan, Liang [1 ]
Zhu, Kedong [1 ]
Luo, Jiaying [1 ]
Zhang, Zhaohui [1 ]
机构
[1] Wuhan Univ, Dept Neurol, Renmin Hosp, Wuhan 430060, Peoples R China
来源
NEUROSCIENCE BULLETIN | 2025年
基金
中国国家自然科学基金;
关键词
Fibrinogen; Tauopathy; Cross-seeding; Alzheimer's disease; PLASMA-FIBRINOGEN; DEMENTIA; RISK; NEUROINFLAMMATION; MATTER;
D O I
10.1007/s12264-025-01366-8
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Vascular damage plays a significant role in the onset and progression of Alzheimer's disease (AD). However, the precise molecular mechanisms underlying the induction of neuronal injury by vascular damage remain unclear. The present study aimed to examine the impact of fibrinogen (Fg) on tau pathology. The results showed that Fg deposits in the brains of tau P301S transgenic mice interact with tau, enhancing the cytotoxicity of pathological tau aggregates and promoting tau phosphorylation and aggregation. Notably, Fg-modified tau fibrils caused enhanced neuronal apoptosis and synaptic damage compared to unmodified fibrils. Furthermore, intrahippocampal injection of Fg-modified tau fibrils worsened the tau pathology, neuroinflammation, synaptic damage, neuronal apoptosis, and cognitive dysfunction in tau P301S mice compared to controls. The present study provides compelling evidence linking Fg and tau, thereby connecting cerebrovascular damage to tau pathology in AD. Consequently, inhibiting Fg-mediated tau pathology could potentially impede the progression of AD.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] The role of neurotrophins and insulin on tau pathology in Alzheimer's disease
    Elliott, Evan
    Ginzburg, Irith
    REVIEWS IN THE NEUROSCIENCES, 2006, 17 (06) : 635 - 642
  • [42] Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer's disease
    Hoglund, Zachary
    Ruiz-Uribe, Nancy
    del Sastre, Eric
    Woost, Benjamin
    Bader, Elizabeth
    Bailey, Joshua
    Hyman, Bradley T.
    Zwang, Theodore
    Bennett, Rachel E.
    ACTA NEUROPATHOLOGICA, 2024, 147 (01)
  • [43] Relationship Between Tau Pathology and Neuroinflammation in Alzheimer's Disease
    Metcalfe, Maria Jose
    Figueiredo-Pereira, Maria E.
    MOUNT SINAI JOURNAL OF MEDICINE, 2010, 77 (01): : 50 - 58
  • [44] Immunotherapy for Targeting Tau Pathology in Alzheimer's Disease and Tauopathies
    Rosenmann, Hanna
    CURRENT ALZHEIMER RESEARCH, 2013, 10 (03) : 217 - 228
  • [45] Cerebrovascular Senescence Is Associated With Tau Pathology in Alzheimer's Disease
    Bryant, Annie G.
    Hu, Miwei
    Carlyle, Becky C.
    Arnold, Steven E.
    Frosch, Matthew P.
    Das, Sudeshna
    Hyman, Bradley T.
    Bennett, Rachel E.
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [46] First insert of tau protein is present in all stages of tau pathology in Alzheimer's disease
    Soltys, K
    Rolkova, G
    Vechterova, L
    Filipcik, P
    Zilka, N
    Kontsekova, E
    Novak, M
    NEUROREPORT, 2005, 16 (15) : 1677 - 1681
  • [47] The complexity of tau in Alzheimer's disease
    Naseri, Nima N.
    Wang, Hong
    Guo, Jennifer
    Sharma, Manu
    Luo, Wenjie
    NEUROSCIENCE LETTERS, 2019, 705 : 183 - 194
  • [48] Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer’s disease and primary tauopathies
    Frederique J. Hart de Ruyter
    Tjado H. J. Morrema
    Jurre den Haan
    Jos W. R. Twisk
    Johannes F. de Boer
    Philip Scheltens
    Baayla D. C. Boon
    Dietmar R. Thal
    Annemieke J. Rozemuller
    Frank D. Verbraak
    Femke H. Bouwman
    Jeroen J. M. Hoozemans
    Acta Neuropathologica, 2023, 145 : 197 - 218
  • [49] Tau immunotherapy for Alzheimer's disease
    Pedersen, Jan Torleif
    Sigurdsson, Einar M.
    TRENDS IN MOLECULAR MEDICINE, 2015, 21 (06) : 394 - 402
  • [50] Tau immunotherapies for Alzheimer's disease
    Hoskin, Justin L.
    Sabbagh, Marwan Noel
    Al-Hasan, Yazan
    Decourt, Boris
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (06) : 545 - 554